Therapeutic Options for the Management of the Cardiorenal Syndrome
Patients with heart failure often present with impaired renal function, which is a predictor of poor outcome. The cardiorenal syndrome is the worsening of renal function, which is accelerated by worsening of heart failure or acute decompensated heart failure. Although it is a frequent clinical entit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.4061/2011/194910 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555333024743424 |
|---|---|
| author | Katerina Koniari Marinos Nikolaou Ioannis Paraskevaidis John Parissis |
| author_facet | Katerina Koniari Marinos Nikolaou Ioannis Paraskevaidis John Parissis |
| author_sort | Katerina Koniari |
| collection | DOAJ |
| description | Patients with heart failure often present with impaired renal function, which is a predictor of poor outcome. The cardiorenal syndrome is the worsening of renal function, which is accelerated by worsening of heart failure or acute decompensated heart failure. Although it is a frequent clinical entity due to the improved survival of heart failure patients, still its pathophysiology is not well understood, and thus its therapeutic approach remains controversial and sometimes ineffective. Established therapeutic strategies, such as diuretics and inotropes, are often associated with resistance and limited clinical success. That leads to an increasing concern about novel options, such as the use of vasopressin antagonists, adenosine A1 receptor antagonists, and renal-protective dopamine. Initial clinical trials have shown quite encouraging results in some heart failure subpopulations but have failed to demonstrate a clear beneficial role of these agents. On the other hand, ultrafiltration appears to be a more promising therapeutic procedure that will improve volume regulation, while preserving renal and cardiac function. Further clinical studies are required in order to determine their net effect on renal function and potential cardiovascular outcomes. Until then, management of the cardiorenal syndrome remains quite empirical. |
| format | Article |
| id | doaj-art-2553d839772b4839976b90b058443924 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-2553d839772b4839976b90b0584439242025-02-03T05:48:28ZengWileyInternational Journal of Nephrology2090-214X2090-21582011-01-01201110.4061/2011/194910194910Therapeutic Options for the Management of the Cardiorenal SyndromeKaterina Koniari0Marinos Nikolaou1Ioannis Paraskevaidis2John Parissis3Heart Failure Unit, 2nd Cardiology Department, Attikon University Hospital, University of Athens, Athens, GreeceHeart Failure Unit, 2nd Cardiology Department, Attikon University Hospital, University of Athens, Athens, GreeceHeart Failure Unit, 2nd Cardiology Department, Attikon University Hospital, University of Athens, Athens, GreeceHeart Failure Unit, 2nd Cardiology Department, Attikon University Hospital, University of Athens, Athens, GreecePatients with heart failure often present with impaired renal function, which is a predictor of poor outcome. The cardiorenal syndrome is the worsening of renal function, which is accelerated by worsening of heart failure or acute decompensated heart failure. Although it is a frequent clinical entity due to the improved survival of heart failure patients, still its pathophysiology is not well understood, and thus its therapeutic approach remains controversial and sometimes ineffective. Established therapeutic strategies, such as diuretics and inotropes, are often associated with resistance and limited clinical success. That leads to an increasing concern about novel options, such as the use of vasopressin antagonists, adenosine A1 receptor antagonists, and renal-protective dopamine. Initial clinical trials have shown quite encouraging results in some heart failure subpopulations but have failed to demonstrate a clear beneficial role of these agents. On the other hand, ultrafiltration appears to be a more promising therapeutic procedure that will improve volume regulation, while preserving renal and cardiac function. Further clinical studies are required in order to determine their net effect on renal function and potential cardiovascular outcomes. Until then, management of the cardiorenal syndrome remains quite empirical.http://dx.doi.org/10.4061/2011/194910 |
| spellingShingle | Katerina Koniari Marinos Nikolaou Ioannis Paraskevaidis John Parissis Therapeutic Options for the Management of the Cardiorenal Syndrome International Journal of Nephrology |
| title | Therapeutic Options for the Management of the Cardiorenal Syndrome |
| title_full | Therapeutic Options for the Management of the Cardiorenal Syndrome |
| title_fullStr | Therapeutic Options for the Management of the Cardiorenal Syndrome |
| title_full_unstemmed | Therapeutic Options for the Management of the Cardiorenal Syndrome |
| title_short | Therapeutic Options for the Management of the Cardiorenal Syndrome |
| title_sort | therapeutic options for the management of the cardiorenal syndrome |
| url | http://dx.doi.org/10.4061/2011/194910 |
| work_keys_str_mv | AT katerinakoniari therapeuticoptionsforthemanagementofthecardiorenalsyndrome AT marinosnikolaou therapeuticoptionsforthemanagementofthecardiorenalsyndrome AT ioannisparaskevaidis therapeuticoptionsforthemanagementofthecardiorenalsyndrome AT johnparissis therapeuticoptionsforthemanagementofthecardiorenalsyndrome |